Mitigating MACE Risk in T2D & ASCVD
Be part of the knowledge.™Mitigating MACE Risk in T2D & ASCVD
What strategies and guidelines can we use to reduce the risk of cardiovascular events in patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD)? Join leading experts in this four-part series to find out.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved.
US22DI00407 December 2022
Episodes 1-4 of 4
Cardiovascular Risk Reduction in Type 2 Diabetes & ASCVD: An Interventional Cardiologist’s Perspective
Heart MattersCardiovascular Risk Reduction in Type 2 Diabetes & ASCVD: An Interventional Cardiologist’s Perspective
Type 2 Diabetes & ASCVD: Cardiovascular Risk Reduction According to the Guidelines
Heart MattersType 2 Diabetes & ASCVD: Cardiovascular Risk Reduction According to the Guidelines
Cardiovascular Risk Reduction for Adults With Type 2 Diabetes & ASCVD: A Collaborative Approach
Heart MattersCardiovascular Risk Reduction for Adults With Type 2 Diabetes & ASCVD: A Collaborative Approach
Treating the Individual: Personalized Care Strategies for Patients With Type 2 Diabetes & ASCVD
Heart MattersTreating the Individual: Personalized Care Strategies for Patients With Type 2 Diabetes & ASCVD
